Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
gastrointestinal transit
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "gastrointestinal transit" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-A0118A
CAS No.: 1354744-91-4
Synonyms: NKTR-118 oxalate; AZ-13337019 oxalate
Target:
Research Areas:
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .
Target:
Cat. No.: HY-108229
CAS No.: 49625-89-0
Synonyms: 6β-Hydroxynaltrexone
Target:
Research Areas:
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .
Cat. No.: HY-108229S
CAS No.: 1435727-11-9
Synonyms: 6β-Hydroxynaltrexone-d3
Cat. No.: HY-W004464
CAS No.: 20980-22-7
Cat. No.: HY-A0118
CAS No.: 854601-70-0
Synonyms: NKTR-118; AZ-13337019
Target:
Research Areas:
Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .
Cat. No.: HY-178236
CAS No.: 2768029-03-2
Target:
Research Areas:
TRPM5 agonist-1 is an orally active TRPM5 agonist with a pEC50 of 8.1. TRPM5 agonist-1 shows excellent selectivity (> 100-fold) versus related cation channels (TRPM8, TRPV1, TRPV4, TRPA1, TRPM4). TRPM5 agonist-1 exhibits locally acting stimulatory effect on gastrointestinal transit in mice. TRPM5 agonist-1 can be used for research on promoting gastric motility .
Cat. No.: HY-109065
CAS No.: 1184662-54-1
Synonyms: DSP-6952 free base
Target:
Research Areas:
Minesapride (DSP-6952 free base) is an orally active, selective 5-HT4 receptor partial agonist. Minesapride enhances gastrointestinal motility, colonic transit and defecation function, and inhibits visceral hypersensitivity. Minesapride does not inhibit/induce cytochrome P450 isozymes, has no significant affinity for hERG, and does not trigger the risk of cardiac ischemia via coronary vasoconstriction. Minesapride can be used in research related to constipation-predominant irritable bowel syndrome, chronic constipation, atonic constipation, spastic constipation, functional constipation and functional dyspepsia .
Cat. No.: HY-W004464R
CAS No.: 20980-22-7
Category:
Category:
Cat. No.: HY-109065A
CAS No.: 1184661-33-3
Synonyms: DSP-6952 hydrobromide
Target:
Research Areas:
Minesapride hydrobromide (DSP-6952 hydrobromide) is an orally active, selective 5-HT4 receptor partial agonist. Minesapride hydrobromide enhances gastrointestinal motility, colonic transit and defecation function, and inhibits visceral hypersensitivity. Minesapride hydrobromide does not inhibit/induce cytochrome P450 isozymes, has no significant affinity for hERG, and does not trigger the risk of cardiac ischemia via coronary vasoconstriction. Minesapride hydrobromide can be used in research related to constipation-predominant irritable bowel syndrome, chronic constipation, atonic constipation, spastic constipation, functional constipation and functional dyspepsia .
Cat. No.: HY-181103
CAS No.: 2059904-64-0
Target:
Research Areas:
ERG-IN-6 (compound (+)-(S)-5a) is a μ-opioid receptor activator with an EC50 of 0.12 nM. ERG-IN-6 also is a hERG (Kv11.1) potassium channel inhibitor with an IC50 of 0.681 μM. ERG-IN-6 can be used for the research of pain .
Cat. No.: HY-W004464S
CAS No.: 1309283-31-5
Research Areas:
2-(1-Piperazinyl)pyrimidine-d8 is the deuterated-labeled 2-(1-Piperazinyl)pyrimidine (HY-W004464). 2-(1-Piperazinyl)pyrimidine is an orally effective α2-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
